Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pavia

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Dermatology and Therapy|September 5, 2022
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective StudyLuigi Gargiulo, Luciano Ibba, Giulia Pavia, et al.
Acta Dermato-Venereologica|October 1, 2021
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective StudyRiccardo G Borroni, Piergiorgio Malagoli, Luigi Gargiulo, et al.
Dermatologic Therapy|May 31, 2022
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Dermatology and Therapy|September 5, 2022
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective StudyLuigi Gargiulo, Luciano Ibba, Giulia Pavia, et al.
Acta Dermato-Venereologica|October 1, 2021
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective StudyRiccardo G Borroni, Piergiorgio Malagoli, Luigi Gargiulo, et al.
Dermatologic Therapy|May 31, 2022
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, et al.
Pageof 2